Welcome to the Lineage Cell Therapeutics second quarter 2022 conference call. At this time, all participants are in a listen-only mode. An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage, and recordings, reproductions, or transmissions of this call without the express written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead. Thank you, Brianna. Good afternoon, and thank you for joining us. A press release reporting our second quarter 2022 financial results was issued earlier today, August 11th, 2022, and can be found on the investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by such forward-looking statements. For a discussion of certain factors that could cause the company's results or performance to differ, we refer you to the forward-looking statements sections in today's press release and in the company's SEC filings, including its most recent annual report on Form 10-K and its subsequent quarterly reports on Form 10-Q. We caution you not to place undue reliance on any forward-looking statements which speak only as of today and are qualified by the cautionary statements and risk factors described in our SEC filings. With us today are Brian Culley, our Chief Executive Officer and Interim Chief Financial Officer, and Gary Hogge, our Senior Vice President of Clinical and Medical Affairs. Brian will provide some prepared remarks, and then he and Gary will be available for questions from analysts. With that, I'd like to turn the call over to Brian. Thanks, Ioana, and good afternoon, everyone. We appreciate you joining us on the call today. As you know, I currently am serving on an interim basis as the company's CFO. Several weeks ago, we initiated a nationwide CFO search with an accomplished recruiting firm, and we already are connected to some great candidates, so I'm hopeful we'll have that position filled soon, and we will update you accordingly. Before I provide the business update today and identify a few events you can look forward to, I typically like to start off with a few general comments about the biotech environment and in particular where I see Lineage within the field of cell therapy. Along those lines, one notable and recent event was yet another non-cancer cell therapy company catching the attention of a much larger acquirer. In this case, I'm of course referring to the acquisition of Viacyte by Vertex. Although many investors focus on the oncology side of cell therapy, and indeed that is where cell therapy has established its strongest foothold, additional success continues to occur among non-cancer cell therapy companies, such as through the acquisitions of Semma, BlueRock, and most recently Viacyte. I would also include the partnership which we struck with Roche and Genentech as another significant event for the field of cell transplant medicine, reflecting positively on both IPS and ES companies, and especially compared to some of the setbacks we've seen with certain mesenchymal or undifferentiated cell therapy companies. As this field matures and more and more clinical data are generated, it increasingly appears that cell transplants, when deployed in the right setting with the right delivery tools, have the potential to become an important new branch of medicine. For this reason and others, Lineage will continue to try and position ourselves as a leader in this space through the combination of internal and partnered product development efforts. Thinking next about where Lineage sits within this emerging and promising field as a business and as an investment, I believe we continue to be in an environment where companies with three key characteristics may be in a better position than others to create value in the coming months and years. Those three characteristics are, one, having multiple years of cash, two, having deals with big pharma companies, and three, having diversification through a portfolio of assets, preferably clinical-stage assets, because those typically offer shorter timelines to approval than do preclinical ones. Those three features, cash, validation, and a pipeline, are attributes of Lineage which I believe put us in a strong position to attract shareholder interest in the months and years ahead. I'd like to touch on each of them briefly today. Starting with cash, it is clear that the biotech industry continues to be in a period of uncertainty and volatility, and for this reason, we have persisted with our disciplined use of capital. As of the end of the second quarter, we had a projected cash runway of at least two years. I will add that those two years do not include any cash milestones from the Roche agreement which we may receive during that period. This runway also does not include any revenues from business development deals, although we are putting greater efforts behind that area as well. As noted in today's press release, we expanded one of our existing agreements last quarter and have initiated multiple discussions for additional corporate alliances which might help fund or otherwise enhance our assets. As you know, we continue to be in close contact with CIRM and intend to seek grant support for the OPC1 program. We may consider CIRM support for other programs as well. As I have said before and can reiterate again today, we believe Lineage continues to be in a period of good financial health, which allows us to focus on creating value across the spectrum of short, medium, and most importantly, long-term timeframes. With respect to the second attribute, validation from big pharma, everyone by now is aware of the alliance we entered into with Roche and Genentech last year for the development of OpRegen for dry AMD with GA, or as it is now called by Roche, RG6501. Although we're not able to share specifics, we're extremely pleased with the progress on OpRegen development since entering our collaboration with Roche and Genentech and the resources which have been allocated to its furtherance. Most of the details are internal to the two companies, but I am able to say that during the second quarter, we made progress across all of the primary functional areas, including clinical, regulatory, and manufacturing technology transfer activities, which are reflected in the additional $4.1 million of revenue recognized in the second quarter. Lineage successfully completed additional manufacturing runs of OpRegen along with their associated CMC activities. We continued with the planned technology transfer activities and held a series of joint advisory and separately joint manufacturing committee meetings, which are collaborative forums for discussion and planning for the next steps for OpRegen and its related activities. Long-term follow-up of patients from the phase I II-A clinical study which Lineage conducted is also ongoing, and most notably, those enrolled patients are still doing well, which supports the multiyear durability of a treatment effect with OpRegen. Bolstered by the compelling body of data which we generated from OpRegen in an early clinical trial, we will continue to work closely with the teams at Roche and Genentech to offer our support and experience and advance OpRegen ever closer to later-stage trials. We believe the results we have observed to date with OpRegen compare favorably against the various efforts focused on complement inhibition, which require a lifetime of frequent dosing, offer only a modest effect on GA progression, and to our knowledge, have no or a minimal effect or benefit on visual acuity. For these reasons and many others, we're excited about generating further clinical data from this program as soon as possible. Thirdly, with respect to the diversification which our promising and recently expanded pipeline offers to investors, the team made excellent progress in multiple areas with a particular focus on advancing certain clinical and regulatory steps which are not only necessary to support any future trials, but also reduce risk across our portfolio. In particular, efforts were made to prepare for regulatory interactions for both our OPC1 and VAC2 programs, which are necessary to support their next phases of clinical testing in spinal cord injury and oncology, respectively. We also continued to engage in manufacturing and preclinical activities for our newly launched cell transplant programs for hearing loss and vision disorders. I'll add that activities which will support our regulatory interactions for OPC1 are nearing completion, which I believe is a positive reflection of our efforts to reduce cell therapy development timelines. Our new thaw and inject formulation of OPC1, which we manufactured via an improved and larger scale process, has been undergoing preclinical testing, and I'm pleased to share today for the first time that our OPC1 cells from the improved formulation and process have successfully demonstrated functional recovery in a clinically relevant animal model for spinal cord injury, including improvement in gait coordination and motor performance, along with cell engraftment, which manifests as a reduction of the area of cavitation in the spinal cord. These findings are consistent with prior data generated from a less efficient and lower scale manufacturing process, so we are delighted that our new and improved process has performed as intended in these studies. We expect that these results will be submitted and available for publication and review. In conjunction with our efforts on the cell side, the other cell side, we have been working on an improved delivery system for OPC1. We believe the novel delivery system, which we licensed from NeuroGain, will offer a safer and easier-to-use method for delivering OPC1, and I'm able to share today that most of the verification and validation activities for this delivery system, including its preclinical testing in support of a regulatory submission, have been completed, which moves us closer to our goal of filing an IND amendment and testing the DFD clinically. With both the cell and delivery activities making excellent progress this past quarter, we have re-engaged with the California Institute of Regenerative Medicine, or CIRM, to open discussions about providing some financial support for this trial. We also have been re-engaging with various industry and caregiver groups such as Spinal Cord Outcomes Partnership Endeavor and the American Spinal Injury Association, as well as with the contemporary thought leadership in spinal cord injuries and with prior study participants. Everything seems to be coming together nicely for the OPC1 program, which I will remind you will include, for the first time, administering OPC1 to patients with chronic spinal cord injuries, not just subacute injuries, in our planned clinical trial to evaluate the safety and performance of the novel delivery device. As OPC1 gets increasingly closer to returning to clinical testing, it's worth remembering why we are so excited to continue this program. Now, I won't repeat my usual comments about the enormous unmet medical need or the absence of any approved treatments, but refer you instead to prior clinical data. The full study results from the 25 patients enrolled in the phase I II-A clinical study in sub-acute cervical spinal cord injury were recently published in the Journal of Neurosurgery: Spine. In that publication, it was reported that OPC1 demonstrated an excellent safety profile, and at one year post-treatment, 96% of patients had recovered one or more levels of neurological function on at least one side of their body, compared to an expected control rate of approximately 68%, according to Steeves et al. In addition, 32% of patients in that study recovered two or more levels of neurological function on at least one side of their body, which again is higher than what Steeves et al. would have anticipated. For these reasons, and because there were many lessons learned from the initial trial of OPC1, which we aim to incorporate into the next study, we are very excited to put OPC1 back into clinical testing and evaluate the potential for our replace and restore technology to provide outsized clinical outcomes in spinal cord injury, not unlike our experience to date with the restoration of retinal tissue observed with OpRegen in the setting of dry AMD. Moving next to our VAC2 program, we have similarly continued to make progress toward an IND submission in preparation for potential U.S. clinical testing next year. I'd like to remind everyone first that Cancer Research UK continues to follow patients in the phase I clinical study of VAC2 in non-small cell lung cancer, and the public release of clinical study results is entirely subject to their discretion and control. However, our team has received all of the necessary clinical information which is required to support the regulatory interactions which we are working toward in the U.S. Depending on the outcome from those FDA interactions, we would be permitted to conduct clinical testing of VAC2 at U.S. centers for the first time. As we work toward those FDA interactions, I can update you today to share that following technology transfer of the VAC2 program from Cancer Research UK to Lineage, the Lineage team engaged in efforts to optimize the manufacturing process. The manufacturing team was able to successfully increase the production scale to a level compatible with early-stage testing while also significantly reducing our cost of goods. I will add that part of the reduction in the cost of goods was due to scale, but a large amount of that reduction was attributable to new methods of production which we deployed. The team also made marked improvements in the purity and functionality of the product candidate reflected in surface marker expression and in vitro functionality tests. I want to diverge for just a moment to highlight something which I think has gone under the radar for some time. These manufacturing achievements which I'm describing today reflect the third time for which Lineage's manufacturing team was able to meet ambitious production goals which were unattainable by multiple prior sponsors and contract manufacturers. Manufacturing specific cell populations in a reproducible and consistent manner is extremely difficult, and doing so using a process that can not only support initial clinical testing but also have a line of sight onto a commercial platform is something we've done twice, first with OpRegen, then again with OPC1, and now we've nearly accomplished it a third time with our dendritic cell program. I don't think we get full credit for our manufacturing capabilities today, but I do think awareness is rising about how the manufacturing portion of cell therapy product development is so critical and how doing it well can greatly reduce development cycles and avoid regulatory delays, the likes of which we have seen at some other companies. I also believe that with additional time and success, the capabilities and know-how of the Lineage manufacturing team will be more fully appreciated. Returning back to our pipeline programs, I'll conclude by adding that we also have continued to advance our auditory neuron and photoreceptor programs. They both are proceeding through the required preclinical development and manufacturing activities which are necessary to support initial clinical testing. As we generate data or have other interesting events which we can share with you can expect updates from time to time on those two programs. Overall, our efforts at this time remain focused on conducting our share of the OpRegen development activities as well as successfully completing a diverse set of regulatory, preclinical, and clinical events for our pipeline, events which will provide not only clarity on our development timelines but also help de-risk and increase the value of our various assets. Because we're doing this work among the tailwinds of multiple years of cash, a big pharma partnership, and a diverse set of unique yet related cell therapy assets, I'm encouraged by what the future may hold for Lineage. A handful of specific goals and objectives which I'd like to invite you to be aware of include a planned interaction with the FDA in Q4, where we intend to discuss our OPC1 IND amendment submission to enable the clinical performance and safety testing of the novel delivery system in acute and chronic spinal cord injury patients. Second, a pre-IND regulatory interaction with the FDA, also in Q4, to seek feedback on a VAC2 CMC non-clinical and clinical package to support U.S. clinical development. Third, evaluation of new partnership opportunities and/or expansion of existing collaborations. You saw recently that we are successful in expanding an existing collaboration with ABM for our HyStem technology and that we continue to work with our partner, Immunomic Therapeutics. We also would like to enter into additional alliances with larger economic benefits to Lineage and are aggressively seeking to identify opportunities to enter into such corporate alliances and help advance our assets. Fourth, we intend to submit a grant application to CIRM for the continued support of the clinical development of OPC1. Fifth, we intend to generate preclinical data to support a pre-IND meeting with the FDA for our new auditory neuron program. We of course have other goals, but the ones I've highlighted today in particular will provide additional regulatory and spending clarity and potential de-risking of our programs. We believe that execution of these goals will continue to demonstrate our ability to successfully advance novel cell therapy product candidates. Okay. With that, let me put on my interim CFO hat and turn next to our financial results. With respect to our balance sheet, we continue to be in a comfortable position as we expect to have more than two years of liquidity, not accounting for any of the Roche Genentech milestones, which we may receive in the next two years, nor for any business development or grant revenues which we may receive. Our reported cash equivalents, and marketable securities as of Q2 totaled approximately $72 million. In comparison, our normalized net operational spending for the past two years was between $20 million and $25 million. Even though we likely will see that amount be closer to $30 million this year, we have more than double that amount in the bank and can continue to just focus on running the business. Total revenues for the second quarter were approximately $4.6 million, an increase of $4 million, representing an increase of over 700% compared to the same period in 2021. The increase was due primarily to licensing fees in connection with the Roche collaboration agreement and reflecting our share of collaboration responsibilities. The largest portion of the activity attributed to this revenue was OpRegen manufacturing costs, but also included personnel, materials, and clinical consulting expenses. As you may recall, we received the $50 million upfront payment from Roche in January on a cash basis, but on a GAAP basis, we are recognizing that $50 million over time as opposed to a point in time, and utilizing an input method of costs incurred over total estimated costs to complete our performance obligations. The accounting recognition for the Roche upfront payment generally resembles a percent complete methodology, but is a reflection of our proportional contribution and may vary from quarter to quarter. Overall, our revenue recognition for the second quarter was largely in line with our expectations. Total operating expenses for the second quarter were approximately $8.6 million, an increase of approximately $1.1 million compared to the same period in 2021. The increase was a result of increased R&D spending of approximately $400 thousand, primarily related to development activities in our new auditory neuron and photoreceptor cell therapy programs, as well as an increase in OpRegen-related expenses to support the Roche collaboration. Furthermore, G&A expenses were up by approximately $700 thousand, mostly related to higher stock-based compensation and payroll and related benefits expense. Our loss from operations for the second quarter was approximately $4.2 million, a decrease of $2 million compared to the same period in 2021, resulting from the aforementioned $4 million increase in revenues and offset with a $1.1 million increase in operating expenses. The net loss attributable to Lineage for the second quarter was $6.8 million or $0.04 per share. As we always say at this point in the call, it's important to remember that the variance between our loss from operations and our overall net loss is impacted by changes in the value of our investments, as well as by foreign currency exchange rate fluctuations related to our international subsidiaries. While these non-operational fluctuations are important, we tend to utilize loss from operations as a more relevant measurement with regard to our clinical programs. Turning to the balance sheet, we reported cash and cash equivalents and marketable securities of approximately $72 million as of quarter end. Additionally, as disclosed as a subsequent event in our recently filed 10-Q, during July, we also received approximately $0.9 million in net proceeds from a warrant exercise at our subsidiary in Israel. As I mentioned earlier, we anticipate a modest increase in our normalized net spending this year compared to the prior year because our programs increased in number and continue to advance toward their next clinical trials, and we have certain performance obligations under the Roche agreement, such as supplying OpRegen cells for the next clinical trial. As I also noted earlier, we estimate our net operational spend for 2022 on a normalized basis will be less than $30 million. Overall, we intend to maintain the same spending discipline that we have adhered to so far and which has served us well in the past. We believe that this spending discipline, alongside our cash balance, puts us in a good position to create value for shareholders from our investments. Our guiding principle at Lineage is to advance the emerging technology of cell transplant medicine and to show the potential for those transplants to outperform traditional approaches by providing the product attributes and rigorous clinical testing necessary to achieve commercially successful medicines in areas of high unmet need. To that end, we believe we have not only generated evocative data from our current clinical programs, but also have the opportunity to do so with our earlier stage initiatives. We've made significant investments in and improvements to areas such as production, scale, purity, and delivery of our differentiated cells, which overall we believe is a proven path to creating best-in-class products for end users and strong competitive advantages to protect Lineage's and our current and potential partners' sales over the long term. We also are working hard to identify and execute on measures which can reduce cell therapy development timelines, which we believe is a new area of opportunity in this young field. Wrapping up, as I speak with you today, we are confident in our cash position, our corporate alliances, and our diverse portfolio of assets from which we can seek to optimize an attractive mix of development partnerships and internally developed programs. There is a lot to like about where we are today and much to anticipate from us in the coming weeks, months, and years. We sincerely appreciate your support as we continue to position Lineage to become a leader in cell therapy and cell transplant medicine. With that, operator, we are ready to respond to any questions from research analysts which may be incoming. Thank you. At this time, I would like to remind everyone in order to ask a question, you must press star followed by the number one on your telephone keypad. We'll pause for just a moment to compile the Q&A roster. Your first question comes from Mayank Mamtani with B. Riley Securities. Your line is now open. Thank you so much. This is William Wood on for Mayank Mamtani. Brian, congratulations to you and the Lineage team for another very productive quarter. Just a couple questions from us here. Just thinking about OPC1, maybe even in terms of OpRegen, where it sometimes takes a little bit longer for the cells to get in and really do what they're supposed to do and to really get the results you're looking for. Obviously already shown very nice results with OPC1 at one year. Just curious about some of the longer-term data for efficacy, potentially maintenance or even improvements, or alternatively degradation of the recovery for your OPC1 treated from the SCiStar or potentially even from earlier trials if the recovery is maintained. Any extra color, that would be great. Yeah, thanks William. Appreciate you and Mayank. So I'll invite Gary Hogge to comment. I think I'll just preface by saying it's a question we all have. I mean, how durable are these cells? They continue to persist in patients and so, you know, potentially they will essentially outlive the people that they are transplanted into. Gary could be a little more specific about how long we monitor patients and how long we've seen these kinds of benefits. Yeah, sure. Thanks, Brian. William, what we've observed to date is that the cells appear to persist at the site of administration, so they don't migrate anywhere, they stay where they were put, and all suggestions on the MRI findings to date would say that they're durable, up to the length of follow-up, which is greater than 10 years in some patients at this point. As you know, we've completed some of the additional animal models, and looked for the durability response in those animals. We begin to think that will follow through with our individual patients. One thing that we're doing shortly is there'll be a manuscript looking at the MRI findings specifically to show that those improvements from the site of administration are maintained for a period of time. As Brian said, sometimes the patients with rehab also continue to improve even if they don't necessarily gain multiple levels on the different assessments. Individual ability to move fingers or digits or wrists can definitely improve quality of life. We're also looking at being able to publish some of those data. Appreciate that extra color, very helpful. Also curious, you know, you've discussed a lot with potential partnerships or collaborations. I'm just curious where you've seen the most interest as far as from external programs looking at your specific internal programs, you know, even considering also, you know, if there's the most interest in manufacturing side of things. Then maybe kind of in addition to that, if there's a scenario where you potentially see sort of your manufacturing side spin out from the clinical development side or something to that degree. Just any extra information there. Yeah. As you know, I can't comment specifically on any discussions or any specific companies. What I'm able to say is that we are aware, in particular in an environment like we're in right now in biotech, that there's tremendous benefit if you have a platform technology of working with multiple corporate partnerships because you're able to just conduct so much more and many more shots on goal. There's so much more productivity when you've got multiple parties working. The challenge for any company is if you have choices, deciding how to sort of, you know, divide up a large either intellectual property estate or different parts of technology and sometimes parts of the technology overlap. For example, there may be certain applications of intellectual property with respect to a manufacturing process which we could deploy across related indications. Sometimes you have to make decisions about where you're going to you know, how you're going to kinda divide up the pie if you have the opportunity to make those choices. We're really keen to accelerate our product development because we obviously cannot manage you know, five simultaneous pivotal trials. We're really supportive and interested in business development. Generally, with respect to more strategic considerations like manufacturing, I can imagine scenarios where utilizing our manufacturing expertise could be valuable to our company, but I want to caution everyone that that does not mean turning into a lower margin manufacturing CRO business. You know, we'll always want to have a meaningful piece of the upside for any program. You know, I wanna be clear that our jobs here involve creating value and sometimes that might mean you go in an unexpected direction in order to create that value, and that's okay. I do think that we recognize that our contribution in getting the best economics from any future deal is going to be driven by having a lot of value behind our contribution and not, I would say, diminishing it or allowing us to get into relationships where we're not going to be paid a fair value for our contribution. I recognize that that is very sort of a generic sort of response for reasons that you're already aware of. Nonetheless, these are the realities of how we view our business and what we have to offer. Yeah, no, that's, it's very helpful. I think I'll leave it there. I appreciate it, Brian. Congratulations again to you and the team, yeah, congratulations. Thank you, William. Your next question comes from Kristen Kluska with Cantor Fitzgerald. Your line is now open. Good afternoon. This is Rick on for Kristen. Thank you for taking our questions. We have two for you here. In the photoreceptor program, with the caveat that of course it's in preclinical development, still ongoing, how are you thinking about potential learnings that might be carried over from the OpRegen program in terms of delivery and the importance of covering affected areas of tissue in the ophthalmology space? Yeah, thanks, Rick. I mean, I think one of the nice things about introducing another ophthalmology program is that there is much that we can learn, and we already have very established relationships in that space. It was an easier area for us to get into. Let me again invite Gary to address some more specifics to your question. Sure. Rick, you know, one thing is we've certainly got the experts in retinal physiology and disease processes at the beck and call at this point, 'cause they're very engaged with the OpRegen data. One thing we learned from OpRegen is delivery is critical. If you make the cells and they are put where they are most functional, they'll do their job as intended. The key learnings for that would be early intervention, appropriate delivery in an area that is, you know, targeted to make a difference. There are a number of diseases that impact the photoreceptors that as you can imagine, and we're certainly open to considering all of those. Okay, maybe just one more. Looking ahead to regulatory interactions around OPC1, how are you thinking about how the preclinical activities that you mentioned could fit into the meeting? What do you believe regulators are looking for here? Well, it's a tough question because, it's sort of a moving answer. You know, I think the FDA has been evolving in its own state of maturation in the field of cell and gene therapy. For example, I think that FDA has been increasingly interested in, functional assay data from cell therapy manufacturers, just to provide one example. We do know that they wanted to see, specific to the OPC1 program, information about the device before they, reviewed the information about the new process that we are utilizing. We're gonna follow a sequential path there that they've outlined for us. This is, I won't say new territory, but there are not a large number of precedents for delivering cells like this to the spinal cord. It's difficult for us to know, and that in fact is part of the reason why we're trying to be comprehensive with our submission and get the agency as much information as we think they're looking for so that we can have some positive outcomes in an area which is breaking some new ground. That's great. Thank you very much. Great. Thank you, Rick. Your next question comes from Joe Pantginis with H.C. Wainwright. Your line is now open. Hey, everybody. Good afternoon. Thanks for taking the question. If you don't mind, I'd like to ask CFO Brian a question first. I appreciate that you give the guidance about, you know, a little under $30 million or so for net spend this year, but I was curious more specifically about the G&A line. That line tends to be a little choppy. Obviously, there are some non-cash items that are included there, but I guess I would ask the question this way. Second quarter number represent a baseline or, you know, how should we sort of view that with regard to the current right sizing of the company's FTEs? Well, thank you, Joe. As you know, this is my second tour of duty as an interim CFO, so of course, I'm well prepared to answer that question. G&A was up about $700,000. A lot of that is in fact related to personnel. I am aware that many companies have been laying people off and that we are a bit of a salmon going in the opposite direction. That's wonderful. I mean, that reflects that we're confident that we have the capital to be able to you know, expand sensibly in this environment. I also believe that we have wonderful choices out there attributable to the fact that some very high caliber companies are laying people off, and those people are going to be increasingly interested in a company like Lineage that has capital and some validation from big pharma, et cetera. So I think that I think that you could consider it to be more of a new baseline rather than a a standalone one-off increase in quarter because a lot of it's connected to personnel, and we want to keep those personnel. I think that's great. You know, change through growth and adding people is also going to turn into greater productivity and, you know, the breadth of what we're able to accomplish. I'm really happy with where we've come in and our continued disciplined use of capital, and I'm particularly excited about some of the new hires that we've made and some of the candidates that we're continuing looking at. No, that's helpful. Then I guess my next question, I mean, it's surrounding Roche, and I know a lot of the details around my question are in the weeds of the confidential documents. I guess I'll ask it this way. How far will you be taking, or what do you feel you could share with us with regard to what your remaining responsibilities are with regard to manufacturing in CMC? You're correct. The weeds are in some places so thick that they're redacting that information, so I'm not able to say really anything beyond what I've shared today. Primarily, our contributions are around manufacturing for the next clinical study, completing the phase I II-A study, which we already completed enrollment for, but we have to follow up patients. We have, you know, assorted additional contributions, largely in the form of sort of advisory. I'd characterize them as advisory contributions. It's really difficult for me to say anything more than that. However, as we do get closer and as some of the public information does get released, it will be easier for us to be able to either connect some dots or be able to make some explicit statements about the program, its timeline, revenue recognition, and everything in between those two. Got it. Got it. Thanks for that. My last question is more of a pie in the sky question. Because look, you're very fortunate to have a strong cash balance, especially in this environment. I'll preface my question by saying, obviously, you have a lot going on. With that said, would you be considering at any point or are you even bothering to look at any potential technologies or assets to bring in that might be complementary because of the depressed valuations that are out there? Thank you for the question. I think the right answer is always yes. I think that in some environments, you're in a stronger position to be able to consider that if you've got a high equity price and a lot of capital. I think the reality is that we are always looking at ways that we can accelerate the development of our programs. Are we spending more time thinking about those opportunities than we were one year ago? Yes. We hired some additional personnel in business development and licensing, and that's one of their areas of effort. I would not say that we have an explicit campaign with narrow search criteria and an engaged investment bank to work on a project that would be beyond the scope of what we're doing. You know, when the phone rings and people want to talk about alliances, we always pick up, and sometimes we're the ones that are dialing. The answer is yes, but I also don't want to make more of it than our normal course of business, looking for ways that we can, you know, add or enhance to our business. Got it. Thank you, Brian. Thank you, Joe. Your next question comes from Jason McCarthy with Maxim Group. Your line is now open. Hey, Brian. Thanks for taking the questions. Two questions. One specific around VAC2, and one more broadly. For VAC2, can you give us a sense of when we could see the Cancer Research UK phase I data in lung? Is that gonna be this year? And how is that data gonna be used to present to regulators for development in the U.S.? My second question is more broadly, you had mentioned the Vertex Viacyte acquisition, but can you talk just a little bit about how what we see is essentially most big pharmas and big biotechs are now aligned or aligning themselves with cell therapy non-oncology initiatives. Yeah, thanks, Dr. McCarthy. So question one is like it's itself a two-parter. When VAC2 and then how would we use it? I'll do part one. So when it's up to Cancer Research UK, and I'll just be very direct that one of the factors that led us to exercising our option to bring that program back was that we felt that it would move quicker in Lineage's hands than where it was. We don't know when that data will be available or published or presented. It's not our decision, and it's not under our control. You know, when it does become available, we certainly will want to share it with everyone. I'll hand off to Gary for how, you know, how the information that we have collected can be useful to a U.S. filing. One thing to keep in mind is that the endpoints as they're shown on ClinicalTrials.gov are, you know, primarily safety at five years and signs of immune effector efficacy at two years. The last patient came on in February of this year, so that person won't hit two years until February of 2024. We've got a ways to go for that patient, hopefully there, 'cause they continue to do well. We have the complete annual safety update. There are no untoward, unexpected adverse events or serious adverse events. It's behaved as expected. Everything's been mild and well-tolerated. Those safety data will contribute to our regulatory submissions and discussions with the agency. Again, we're focused on the FDA, but there are other regulatory bodies that we'd like to potentially consider as well. Returning back to your second question, this is a really exciting time in cell therapy because I think what we're seeing, it would be a debated point, but my view of what we're seeing is that as data continues to be generated, the most promising data, in my mind, is emerging in the area of differentiated cell types, you know, going after areas like type one diabetes and Parkinson's. It's not with the undifferentiated, quote, "adult cells," the mesenchymal cells from adipose or umbilical cell. I think what's exciting in the seat that I sit in at Lineage, and is shared with some of the companies that you have in mind when you're asking this question, are these non-oncology, so i.e., non-T cell, non-NK cell, specific differentiated cell types that are used much like a bone marrow transplant. You are just manufacturing the cell type. The cell has a specific function. You deliver it. You have to have a solution for how it can remain durable and not be rejected. If the cells are there and they're functional, they may be able to provide that normal, natural biological function that is somehow lost under certain conditions, like dry AMD with GA or Parkinson's disease or diabetes. I agree with you entirely that it seems that, more and more interest is being reflected by, the international, you know, big pharma community, and they are, sometimes making baby steps, sometimes making massive bites. But there does seem to be a trend in this direction, which I think is incredibly exciting because it is still a relatively early technology, and early technologies get better with time. I think you're going to see explosive growth in this field. I've been saying that for a couple of years, and I think there's increasingly, evidence to support that, and it'll just be a question of, you know, how high is the ceiling on this? I believe it's very high indeed. Great. Thank you for taking my question. There are no further questions at this time. This concludes today's conference call. You may now disconnect. Thank you, everyone.